CD34⁺ cell enrichment depletes atypical CD30⁺ cells from PBPC grafts in patients with HD

By Blystad AK   Torlakovic E   Holte H   Kvaløy S   Lenschow E   Kvalheim G  

Cytotherapy, Vol. 3, Iss. 4, 2001-07 ,pp. : 295-305

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Selected CD34 blood cell allografts for older patients: low transplant-related mortality, graft failure and acute GvHD

By Roberts Mm   Dyson P   Rawling C   Thorp D   Rawling T   White D   Horvath N   Bardy P   Hui Ch   Dart Gw   To Lb   Hughes Tp  

Cytotherapy, Vol. 5, Iss. 6, 2003-12 ,pp. : 534-541

Ashgate Publishing Ltd

Access to resources Recommend Favorite

A comparison of CFU-GM, BFU-E and endothelial progenitor cells using ex vivo expansion of selected cord blood CD133+ and CD34+ cells

By Lu X.   Baudouin SV   Gillespie JI   Anderson JJ   Dickinson AM  

Cytotherapy, Vol. 9, Iss. 3, 2007-01 ,pp. : 292-300

Ashgate Publishing Ltd

Access to resources Recommend Favorite

CliniMACS CD34^-selected cells to support multiple cycles of high-dose therapy

By Prince HM   Wall D   Rischin D   Toner GC   Seymour JF   Blakey D   Haylock D   Simmons P   Wolf M   Januszewicz EH   Westerman D   Richardson G   Scarlett J   Briggs P  

Cytotherapy, Vol. 4, Iss. 2, 2002-03 ,pp. : 147-155

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Isolex 300i CD34^-selected cells to support multiple cycles of high-dose therapy

By Prince HM   Bashford J   Wall D   Rischin D   Parker N   Toner GC   Seymour JF   Blakey D   Haylock D   Simmons P   Francis P   Wolf M   Januszewicz EH   Richardson G   Scarlett J   Briggs P  

Cytotherapy, Vol. 4, Iss. 2, 2002-03 ,pp. : 137-145

Ashgate Publishing Ltd

Access to resources Recommend Favorite